INF ASH 2013

8/13/2019 INF ASH 2013

1/40

ASH 2013

December 8, 2013

8/13/2019 INF ASH 2013

2/40

Forward Looking Statement

2

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.

Such forward-looking statements include those regarding the Companys expectations about: its ability to execute on its strategic

plans; the therapeutic potential of PI3K inhibition and IPI-145; management of infectious complications; and the potential rationale

of investigating IPI-145 in additional indications and combinations therapies. Such statements are subject to numerous important

factors, risks and uncertainties that may cause actual events or results to differ materially from the companys current

expectations. For example, there can be no guarantee that Infinity will initial clinical trials or report data in the time frames it has

estimated, that any product candidate Infinity is developing will successfully complete necessary preclinical and clinical

development phases or that development of any of Infinitys product candidates will continue. Further, there can be no guarantee

that any positive developments in Infinitys product portfolio will result in stock price appreciation. Managements expectationsand, therefore, any forward-looking statements in this presentation could also be affected by risks and uncertainties relating to a

number of other factors, including the following: Infinitys results of clinical trials and preclinical studies, including subsequent

analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions made by the

U.S. FDA and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies;

Infinitys ability to obtain and maintain requisite regulatory approvals and to enroll patients in its clinical trials; unplanned cash

requirements and expenditures; development of agents by Infinitys competitors for diseases in which Infinity is currently

developing, or intends to develop, its product candidates; and Infinitys ability to obtain, maintain and enforce patent and other

intellectual property protection for any product candidates it is developing. These and other risks which may impact

managements expectations are described in greater detail under the caption Risk Factors included in Infinitys quarterly reporton Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 7, 2013, and other filings filed by Infinity

with the SEC. Any forward-looking statements contained in this presentation speak only as of the date hereof, and Infinity

expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future

events or otherwise. Infinitys website is http://www.infi.com. Infinity regularly uses its website to post information regarding its

business, product development programs and governance. Infinity encourages investors to use www.infi.com, particularly the

information in the section entitled Investors/Media, as a source of information about Infinity. References to www.infi.com in this

presentation are not intended to, nor shall they be deemed to, incorporate information on www.infi.com into this presentation by

reference.

8/13/2019 INF ASH 2013

3/40

Investigator Disclosures

Ian Flinn, M.D., Ph.D., Director, Hematologic Malignancies Research Program,

Sarah Cannon Research Institute Infinity Pharmaceuticals, Inc. (research funding)

Susan OBrien, M.D.,Ashbel Smith Professor and Chief, Section of Acute

Lymphocytic Leukemia, Department of Leukemia, University of Texas M.D.Anderson Cancer Center

Infinity Pharmaceuticals, Inc. (research funding, consultant)

Gilead Sciences (research funding, consultant)

Pharmacyclics, Inc. (research funding, consultant)

John Gribben, M.D., Hamilton Fairley Chair of Medical Oncology, Barts CancerInstitute, Queen Mary, University of London, UK Roche/Genentech (consultant),

Celgene Corporation (consultant, research funding)

3

8/13/2019 INF ASH 2013

4/40

Agenda

Introduction: Julian Adams, Ph.D., President of R&D, Infinity Pharmaceuticals, Inc.

Overview of IPI-145 Phase 1 Data in Hematologic Malignancies: Dr. Julian Adams

IPI-145 Phase 1 Data in CLL: Ian Flinn, M.D., Ph.D., Sarah Cannon Research Institute

Panel Discussion/Q&A: Dr. Julian Adams (moderator)

Dr. Pedro Santabarbara, Chief Medical Officer, Infinity Pharmaceuticals

Dr. David Roth, SVP Clinical Development and Medical Affairs, Infinity Pharmaceuticals

Dr. Ian Flinn

Dr. John Gribben

Dr. Susan OBrien

4

8/13/2019 INF ASH 2013

5/40

ASH 2013

December 8, 2013

8/13/2019 INF ASH 2013

6/40

IPI-145: Potential to Transform the Standard of Care

in Hematologic Malignancies

6

Highly active in both B-cell and T-cell malignancies

Generally well tolerated

Most AEs are low-grade and/or asymptomatic

Consistent with co-morbidities in patients with advanced hematologicmalignancies

Others experience with BCR inhibitors and our own experience in

our trials has informed our strategies to optimize use of IPI-145

Phase 2 and Phase 3 registration trial under way

8/13/2019 INF ASH 2013

7/40

8/13/2019 INF ASH 2013

8/40

IPI-145 Highly Active in R/R iNHL: 73% ORR

8Douglas et al., ASH 2013.

73% ORR includes one Waldenstrm Macroglobulinemia patient with a minor response (MR)

without adenopathy (not shown above)

Maximum Change in Adenopathy: iNHL Patients Dosed 25 mg BID (n=15)

8/13/2019 INF ASH 2013

9/40

IPI-145 Rapid Response in iNHL: Majority of

Responses Occur by the End of Cycle 2

9R/R iNHL patients, n=15 ( 25 mg BID)

8/13/2019 INF ASH 2013

10/40

IPI-145 Early Evidence of Durable Responses in iNHL53% (8 of 15 Patients) Progression Free for Over One Year

R/R iNHL patients, n=15 ( 25 mg BID)

Douglas et al., ASH 201310

8/13/2019 INF ASH 2013

11/40

R/R CLL

98% (42/43) achieved a reduction in adenopathy by CT assessment, all doses

89% (24/27) nodal response rate ( 50% reduction in adenopathy), 25 mg BID

Treatment-nave CLL

Nodal responses in 3/6 patients, including 2 patients with p53 mutation, 25 mg BID

Flinn et al., ASH 2013

IPI-145 Highly Active in R/R CLL: 89% Nodal Responses

at 25 mg BID Based on Objective CT Assessments

11

8/13/2019 INF ASH 2013

12/40

IPI-145 Early Evidence of Activity in T-Cell Lymphomas


Population

Patients(n)

Best Responsen (%)

Evaluable ORR CR PR SD PD

TCL 26 10 (38) 1 (4) 9 (35) 7 (27) 9 (35)

C-TCL 14 4 (29) 0 4 (29) 7 (50) 3 (21)

P-TCL 12 6 (50) 1 (8) 5 (42) 0 6 (50)

C-TCL = cutaneous TCL; P-TCL = peripheral TCL

Early evidence of activity in C-TCL and P-TCL with IPI-145 up to 75 mg BID

Safety profile in line with comorbidities seen in patients with advanced hematologic

malignancies (Horwitz et al, ICML 2013; Douglas et al, ASH 2013)

8/13/2019 INF ASH 2013

13/40

IPI-145 Early Evidence of Activity in

Aggressive B-cell NHL

13Campbell et al., ASH 2013

Doses up to 75 mg BID (n=14)

8/13/2019 INF ASH 2013

14/40




- Most common AEs were asymptomatic laboratory abnormalities

- Symptomatic Grade 3/4 AEs were uncommon



- Asymptomatic ALT/AST elevation, predominantly in lymphoma to date,

is managed with dose interruptions and re-treatment- Management of infectious complications has evolved to support

continued treatment

14

IPI-145 is generally well tolerated

8/13/2019 INF ASH 2013

15/40

CLL: In This Disease Population, Infections Are

Common, Particularly in Heavily Pre-Treated Patients

Literature reports indicate that fludarabine treated patients have a

high incidence (89%) of infections that require hospitalization for IV

antibiotics*

In newly diagnosed patients treated with ibrutinib, the Grade 3

infection rate was ~10% in treatment-naive patients and ~40% inR/R and high-risk patients**

Consistent with the clinical recommendations in NCCN guidelines,

routine prophylaxis and other treatment recommendations were

introduced into ongoing studies of IPI-145

15*Perkins et al., Cancer2002**Byrd et al., ASH 2012

Following implementation of these recommendations, we have

observed no opportunistic infections and patients with infections

have been able to continue treatment with IPI-145

8/13/2019 INF ASH 2013

16/40

IPI-145: Maintaining Patients on Study Going Forward

Adverse Event Expected Management in Phase 3 Study

Pneumonitis

Early intervention; drug interruption until resolution;

retreat with same dose

Steroids allowed

ALT/AST Dose interruption until resolution; retreat with same dose

Diarrhea Dose interruption until resolution; retreat with same dose

Steroids allowed

Infections

Drug interruption during active infection and antibiotics as

indicated and recommended for immunocompromised

patients; retreat with same dose

16

8/13/2019 INF ASH 2013

17/40

DYNAMO: Phase 2 Study of IPI-145 in

Refractory iNHL Enrolling

Open-label, single-arm monotherapy study under way

Primary endpoint: Objective response rate

*Includes follicular lymphoma (FL), marginal zone lymphoma (MZL), small lymphocytic lymphoma (SLL)

Clinicaltrials.gov NCT01882803.

~120 iNHL patients*IPI-145

(25 mg BID)

17

8/13/2019 INF ASH 2013

18/40

DUO: Phase 3 Study of IPI-145 in R/R CLL

Now Enrolling

Randomized, monotherapy study

Primary endpoint: Progression-free survival by

independent review

~300 patients R

IPI-145 (25 mg BID)(n = ~150)

Ofatumumab (IV)(n = ~150)

18

Clinicaltrials.gov NCT02004522.

8/13/2019 INF ASH 2013

19/40

Phase 1 Exploration OngoingTBD

DUO Phase 3

Phase 1b/2 (+Rit, +Bend, +Rit/Bend)*

Mono Rx

Combo

DYNAMO Phase 2

Phase 1b/2 (+Rit, +Bend, +Rit/Bend)*

Mono Rx

Combo

Realizing Potential of IPI-145 in

Hematologic Malignancies

19

R/R iNHL

R/R

CLL

Phase 1b/2 (+Rit, +Bend, +Rit/Bend)*Combo

Other(T-cell , aNHL)

*Investigator sponsored trial

8/13/2019 INF ASH 2013

20/40

Agenda







Dr. Ian Flinn

Dr. John Gribben

Dr. Susan OBrien

20

8/13/2019 INF ASH 2013

21/40

CLL Cohort 1 (n = 28)R/R 25 mg BID

Phase 1 Trial of IPI-145 in Hematologic MalignanciesPreliminary Outcomes in CLL

Flinn et al., ASH 2013.21

CLL Cohort 2 (n = 24)R/R 75 mg BID

CLL Cohort 3 (n = 15)

Tx-Nave 25 mg BID( 65 years or 17p(del) / p53 mutation)

8/13/2019 INF ASH 2013

22/40

R/R CLLn=52

Tx-Nave CLLn=15

Age (years), median (range) 66 (51-82) 74 (49-83)

Females, n (%) 11 (21) 4 (27)

ECOG Status 0 / 1 / 2, n 11 / 37 / 3 5 / 9 / 1

Prior Systemic Therapies, median (range) 4.5 (1-12) n/a 3 Prior Systemic Therapies 81% n/a

< 6 Months Since Last Therapy 61% n/a

Stage 3 (High-Risk) 73% 53%

Extent of CLL

Bulky Lymphadenopathy (> 5 cm lesion) 49% (23/47) 0Organomegaly 30% (13/43) 50% (7/14)

ALC (x103cells/L), median (range) 13 (0.6-280) 68 (10-204)

17p(del) or p53 mutation 53% (21/40) 54% (7/13)

Prior BTK-inhibitor Therapy, n 4 n/a

CLL Patient Characteristics Representative of the

Populations Under Study


8/13/2019 INF ASH 2013

23/40

8/13/2019 INF ASH 2013

24/40

Relapsed/Refractory (n=52) Treatment-Nave (n=15)

All Grades

%

Grade 3

%

Grade 4

%

All Grades

%

Grade 3

%

Grade 4

%

Neutropenia 46 17 13 7 0 7

Rash (combined) 33 2 2 0 0 0

Diarrhea 29 6 0 20 0 0

Fatigue 29 4 0 7 7 0

Cough 25 4 0 13 0 0

Pyrexia 25 2 0 0 0 0

Nausea 21 0 0 7 0 0

ALT / AST 19 6 0 7 7 0

Anemia 19 12 0 7 0 0

Arthralgia 15 0 0 0 0 0

Peripheral edema 15 0 0 13 0 0

R/R CLL: Median time on treatment = 5.1 months

Treatment-nave: Median time on treatment = 2.7 months

CLL AEs*: Majority of AEs Are Manageable,

Asymptomatic and/or Low Grade


* All Causality 15% in R/R CLL

8/13/2019 INF ASH 2013

25/40

Stability of Mean Peripheral Blood Counts During

IPI-145 Therapy in CLL Patients

C1D1(32)

C2D1(25)

Screening(n) patients

C3D1(22)

C4D1(18)

C5D1(14)

C6D1(13)

ANC

Platelets

Hemoglobin

g/dL

10

11

12

40

120

240

103/ L

103/ L

13

80

200

14

15

160

Mean SD

0

2

1

54

3

6

25Flinn et al., ICML 2013

AE G d 3 i CLL P ti t 25 BID

8/13/2019 INF ASH 2013

26/40

AEs Grade 3 in CLL Patients 25 mg BID (All Causality 5%)Hematologic and Infectious AEs More Common in Heavily Pretreated

R/R CLL Patients


8/13/2019 INF ASH 2013

27/40

R/R CLL

98% (42/43) achieved a reduction in adenopathy by CT assessment, all doses

89% (24/27) nodal response rate ( 50% reduction in adenopathy), 25 mg BID

Treatment-nave CLL

Nodal responses in 3/6 patients, including 2 patients with p53 mutation, 25 mg BID


IPI-145 Highly Active in R/R CLL: 89% Nodal Responses

at 25 mg BID Based on Objective CT Assessments

27

8/13/2019 INF ASH 2013

28/40

Population

Patients(n)

Best Response(n)

ORR by IWCLL

(CR + PR)

(%)Evaluable CR PR SD PD

Overall R/R CLL 47 1 21 24 1 47

25 mg BID 27 1 12 13 1 48

17p(del) or p53mut 12 0 6 5 1 50

75 mg BID 20 0 9 11 0 45

17p(del) or p53mut 7 0 2 5 0 29

Median time to response was < 2 months


IPI-145 Highly Active in R/R CLL: IWCLL Responses

28

Ti St d R/R CLL P ti t t 25 BID

8/13/2019 INF ASH 2013

29/40

Time on Study: R/R CLL Patients at 25 mg BIDEarly Patient Experiences Inform Potential to Optimize Future Patient

Management

29Flinn et al., ASH 2013

Long-term

progression free

Patients enrolled in 2013,Progression free, data maturing

Discontinued

All discontinuationsfrom patients enrolled

before 2013

75% (6/8) patients treated for 1 year remain progression-free on treatment

8 recently enrolled patients (< 6 months) in early follow-up for PFS

8/13/2019 INF ASH 2013

30/40



30

Highly active in both B-cell and T-cell malignancies

Generally well tolerated


Consistent with co-morbidities in patients with advanced hematologicmalignancies



Phase 2 and Phase 3 registration trial under way

8/13/2019 INF ASH 2013

31/40

Agenda







Dr. Ian Flinn

Dr. John Gribben

Dr. Susan OBrien

31

8/13/2019 INF ASH 2013

32/40

ASH 2013

December 8, 2013

8/13/2019 INF ASH 2013

33/40

Back-ups

33

8/13/2019 INF ASH 2013

34/40

Phase 1 Study of IPI-145 in Hematologic Malignancies

Dose Escalation

8 100 mg BID

75 mg BID

MTD Expansion Cohorts

R/R CLL/SLL, iNHL, MCL

T-cell lymphomas

Aggressive B-cell lymphoma

Myeloid neoplasms

Acute lymphoblastic leukemia

25 mg BID

Expansion Cohorts

R/R CLL/SLL, iNHL, MCL

High-risk / Tx-nave CLL

34

8/13/2019 INF ASH 2013

35/40

Non-Infinity References Included in This Presentation

35

8/13/2019 INF ASH 2013

36/40

Ibrutinib Infections in CLLASH 2012

36Byrd et al., ASH 2012.

8/13/2019 INF ASH 2013

37/40

Ibrutinib Infections in CLLNew England Journal of Medicine 2013

37Byrd et al., NEJM2013.

8/13/2019 INF ASH 2013

38/40

Ibrutinib Infections in CLLNew England Journal of Medicine 2013

38Byrd et al., NEJM2013.

Fludarabine Refractory CLL

8/13/2019 INF ASH 2013

39/40

Fludarabine-Refractory CLL89% of refractory CLL patients reported to have disease

(non drug) related serious infections

39Perkins et al., Cancer 2002.

Fludarabine Refractory CLL

8/13/2019 INF ASH 2013

40/40

Fludarabine-Refractory CLL89% of refractory CLL patients reported to have disease

(non drug) related serious infections

40P ki t l C 2002

CONCLUSIONS

The current data show that the frequency of infections serious enough to require

hospitalization for intravenous antibiotics in patients with fludarabine-refractory CLL/SLL

is extremely high. These infections occurred frequently even in the setting of

conventional chemotherapy. As a result of this propensity for infection, caution should be

exercised in interpreting the frequency of infections seen during development of

promising new treatment modalities

INF ASH 2013

Documents

Transcript of INF ASH 2013